Mark Coleman

Director Mark Coleman sold 17,537 shares over 3 days (May 29–Jun 2) for $4,019,470.43 via scheduled 10b5-1 plan at AXSM

Mark Coleman, a Director at Axsome Therapeutics, executed 3 separate sales totaling 17,537 shares for $4,019,470.43 between May 29 and June 2, 2026, reducing his holdings by 37.2% to 29,603 shares post-transaction. This disposition was effected through a pre-arranged 10b5-1 trading plan—a scheduled, non-discretionary mechanism—so the timing and execution reflect contractual commitment rather than a discretionary market timing decision. The company remains unprofitable with a full-year net income of $-64,542,000.00, though it is growing revenue at an annual rate of +65.6%. Across his prior 3 sales at this ticker, Coleman's average 90-day return was +45.6%, indicating that his prior open-market dispositions at AXSM were followed by stock appreciation; however, the current stock price of $245.64 is only 1.3% above its 52-week high of $242.41, and this scheduled 10b5-1 execution carries no forward-looking signal independent of the plan's predetermined terms.

Director Coleman Mark sold 25,000 AXSM shares at $161.11 (Feb 26), reducing stake to 47,140 shares (-34.7%)

Director Coleman Mark executed a significant reduction of his AXSM position, selling 25,000 shares (34.7% of his pre-transaction holdings) at $161.11 on 2026-02-26. The transaction is material in size ($4.0M) and represents a substantial trimming of his stake from 72,140 to 47,140 shares. His prior trades at AXSM (three separate purchases on 2025-09-08) have tracked positive 90-day returns ranging from 17.1% to 17.3%, consistent with a 100% win rate across his cross-ticker buy history, suggesting informed entry timing. The current price of $163.89 stands -13.3% from the 52-week high and -11.5% over the last 30 days, placing this sale within a recent downward drift despite the stock's +8.2% 90-day performance. The company remains unprofitable (net income $-47.2M over the last full fiscal year) while maintaining strong revenue growth of +65.6% year-over-year, a profile typical of high-growth but cash-negative biotech or therapeutics businesses.

Director Coleman Mark purchased 1,575 shares at blended $127.28 (3 transactions 2025-09-08)

Coleman Mark, a director at Axsome Therapeutics, executed 3 separate purchases on 2025-09-08 totaling 1,575 shares for $200,466.30, increasing his holdings from 46,637 to 48,212 shares (+3.4%). The purchases occurred at prices ranging from $127.20 to $127.40 against a current price of $125.68—a location near the middle of the 52-week range ($80.05–$137.75). Over the past month, AXSM stock has appreciated +19.9%, and the company demonstrates strong fundamentals with annual revenue growth of +42.5% on $150.0M in latest quarterly revenue, though the firm remains unprofitable with $-48.0M net income. Notably, Mark's prior two transactions at this ticker (both sells in 2023-09-15) exhibited a 100% well-timed rate at the 90-day mark, suggesting his historical patterns at AXSM have been favorable; however, the present transaction is a buy executed after recent price strength, not preceded by the depressed pricing that characterized his prior dispositions.